Skip to main content
. Author manuscript; available in PMC: 2008 Oct 27.
Published in final edited form as: J Clin Oncol. 2005 Dec 1;23(34):8620–8628. doi: 10.1200/JCO.2005.02.6252

Table 1.

Use of Hematopoietic Growth Factors for Patients With Breast Cancer in Association With Patient Characteristics, Year of Diagnosis, and Geographic Areas

Patient and Tumor Characteristic No. of Patients With Breast Cancer Who Received Chemotherapy Percentage of Patients Receiving Filgrastim Percentage of Patients Receiving Epoetin
Age, years
 65-69 2,780 17.5 6.9
 70-74 1,623 18.9 7.2
 75-79 944 17.9 6.6
 ≥ 80 496 9.7 5.2
Race
 White 5,169 17.6 6.7
 Black 470 13.0 7.2
 Other 204 20.1 7.8
Marital status
 Married 2,776 18.3 7.0
 Unmarried 2,918 16.5 6.6
 Unknown 149 14.8 7.4
Comorbidity scores
 0 3,838 17.9 6.7
 1 1,287 17.2 7.0
 2 463 16.2 6.5
 ≥ 3 255 10.6 8.2
Household income
 1st quartile (< $38,237) 1,405 14.7 6.2
 2nd quartile ($38,237-$47,459) 1,397 17.1 5.4
 3rd quartile ($47,460-$60,582) 1,403 18.9 8.1
 4th quartile (> $60,582) 1,400 18.1 7.8
 Unknown/missing 238 18.9 5.0
SEER registry areas
 San Francisco, CA 389 21.1 6.9
 Connecticut 901 13.5 5.7
 Detroit, MI 1,020 19.6 7.1
 Hawaii 87 11.5 4.6
 Iowa 645 13.8 3.1
 New Mexico 219 13.2 2.7
 Seattle, WA 498 10.6 8.6
 Utah 322 16.2 4.0
 Atlanta, GA 455 22.9 11.9
 San Jose-Monterey, CA 337 20.5 12.8
 Los Angeles, CA 970 20.6 6.6
Year of diagnosis
 1992 629 0 0
 1993 560 3.9 0
 1994 599 16.5 0.8
 1995 658 17.3 5.2
 1996 654 20.3 6.7
 1997 849 19.4 7.5
 1998 909 23.0 9.1
 1999 985 27.2 17.0
Total 5,843 17.3 6.8

Abbreviation: SEER, Surveillance, Epidemiology, and End Results.